Urgent

Pulmonary hypertension — classification & work-up

WHO groups 1-5 · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pulmonary hypertension is defined haemodynamically (mean pulmonary artery pressure >20 mmHg) and classified into five groups with different causes and treatments. Distinguishing pre-capillary (arterial, lung, thromboembolic) from post-capillary (left heart) disease is essential before any targeted therapy.

Red flags

  • Syncope or presyncope
  • Signs of right heart failure (ascites, oedema, raised JVP)
  • Rapid functional decline
  • Hypotension / low cardiac output

Assessment

Differential diagnosis

  • Group 1 pulmonary arterial hypertension
  • Group 2 PH due to left heart disease
  • Group 3 PH due to lung disease/hypoxia
  • Group 4 chronic thromboembolic PH
  • Group 5 multifactorial/unclear mechanisms

Investigations

  • Transthoracic echocardiography (estimated systolic PAP, RV size/function)
  • ECG and NT-proBNP
  • V/Q scan to exclude chronic thromboembolic disease
  • Pulmonary function tests and HRCT for lung disease
  • Right heart catheterisation (confirm mPAP, wedge pressure, pulmonary vascular resistance, vasoreactivity)
  • Connective-tissue, HIV, liver and congenital-heart work-up for group 1

Management

  • Confirm suspicion with echocardiography and assess right ventricular function
  • Systematically exclude left heart disease and lung disease as predominant causes
  • Perform a V/Q scan to detect chronic thromboembolic disease
  • Refer suspected pre-capillary or group 1/4 disease to an expert pulmonary hypertension centre
  • Confirm the diagnosis and group with right heart catheterisation
  • Perform acute vasoreactivity testing in idiopathic/heritable PAH
  • Treat the underlying cause in group 2 (heart) and group 3 (lung/hypoxia) rather than giving PAH drugs
  • Initiate group-1 targeted combination therapy risk-stratified at an expert centre
  • Refer group-4 disease for endarterectomy/angioplasty assessment
  • Provide supportive care (oxygen, diuretics, rehabilitation, anticoagulation where indicated) and structured follow-up

Drugs & doses

Group 1: combination endothelin-receptor antagonist (e.g. ambrisentan 10 mg PO daily) + PDE5 inhibitor (e.g. tadalafil 40 mg PO daily)
Prostacyclin pathway agents (e.g. selexipag, IV/SC treprostinil, epoprostenol) for higher risk
Diuretics (furosemide) for right heart failure
Oxygen for hypoxaemic group 3 disease; avoid PAH drugs in uncomplicated group 2/3

Disposition

Expert pulmonary hypertension centre for groups 1 and 4; treat underlying disease for groups 2, 3 and 5.

Complications & pitfalls

  • Progressive right heart failure
  • Sudden cardiac death
  • Arrhythmia
  • Haemoptysis

Exam pearls

  • Do not treat group 2 (left heart) or uncomplicated group 3 PH with PAH-specific vasodilators — risk of harm
  • Right heart catheterisation is mandatory to confirm and classify before targeted therapy
  • A V/Q scan is essential to avoid missing curable CTEPH
  • Only a minority of idiopathic PAH are vasoreactive and suitable for calcium-channel blockers

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.